Deals Of The Week: GSK’s Stealth Move To The Coasts
The British pharma opens new innovation centers in San Diego and Cambridge, Mass., to connect with those academic, business and venture investment communities. Also, Roche and Biogen Idec make moves in neurodegenerative disease, Retrophin makes two deals for different forms of the same drug, and GSK makes the latest alliance in the cancer immunology arena.
You may also be interested in...
The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.
The British pharma has financed a new venture fund to create a presence in an emerging technology and help jump-start the fledgling industry because it believes that the science has reached a transition point.
The collaboration is the third in its localized Centers for Therapeutic Innovation project, intended to nudge academics toward commercial projects.